Wilmington Savings Fund Society FSB Reduces Position in Pfizer Inc. $PFE

Wilmington Savings Fund Society FSB trimmed its holdings in Pfizer Inc. (NYSE:PFE) by 7.9% in the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 267,838 shares of the biopharmaceutical company’s stock after selling 23,033 shares during the quarter. Wilmington Savings Fund Society FSB’s holdings in Pfizer were worth $6,825,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in PFE. Curio Wealth LLC grew its position in Pfizer by 36,600.0% in the 2nd quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 1,098 shares during the period. Harbor Asset Planning Inc. bought a new stake in shares of Pfizer during the 2nd quarter valued at about $29,000. Howard Hughes Medical Institute purchased a new stake in shares of Pfizer during the 2nd quarter valued at about $30,000. True Wealth Design LLC lifted its stake in shares of Pfizer by 302.5% in the 3rd quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 974 shares during the period. Finally, Darwin Wealth Management LLC purchased a new position in shares of Pfizer in the second quarter worth approximately $32,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analysts Set New Price Targets

PFE has been the topic of several analyst reports. Bank of America dropped their price target on shares of Pfizer from $29.00 to $28.00 and set a “neutral” rating on the stock in a research note on Monday, December 15th. The Goldman Sachs Group reiterated a “neutral” rating and set a $26.00 target price on shares of Pfizer in a research report on Wednesday, November 5th. Wolfe Research set a $24.00 price target on Pfizer and gave the stock an “underperform” rating in a research report on Wednesday, December 17th. Morgan Stanley cut their price objective on Pfizer from $32.00 to $28.00 and set an “equal weight” rating for the company in a research note on Friday, December 12th. Finally, Wall Street Zen cut shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, thirteen have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Pfizer presently has a consensus rating of “Hold” and an average price target of $27.88.

Pfizer Stock Down 0.8%

PFE opened at $25.68 on Friday. The company has a market capitalization of $146.01 billion, a PE ratio of 14.93 and a beta of 0.47. The firm has a 50-day simple moving average of $25.35 and a two-hundred day simple moving average of $24.99. The company has a quick ratio of 0.97, a current ratio of 1.28 and a debt-to-equity ratio of 0.62. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $27.69.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, topping analysts’ consensus estimates of $0.79 by $0.08. The company had revenue of $16.65 billion for the quarter, compared to the consensus estimate of $16.94 billion. Pfizer had a return on equity of 20.17% and a net margin of 15.65%.Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 23rd will be given a dividend of $0.43 per share. The ex-dividend date is Friday, January 23rd. This represents a $1.72 annualized dividend and a yield of 6.7%. Pfizer’s dividend payout ratio (DPR) is 100.00%.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.